Theorist position for analysis AD-MASTER-PLAN-GFAP-20260428030756: AD Master Plan preregistration: GFAP
Context: Preregistered claim: GFAP-positive reactive astrocytes mediate regional vulnerability through dysfunction of metabolic support, driving AD progression in affected regions
Primary claim: GFAP-positive reactive astrocyte states as mediators of regional metabolic vulnerability in AD is a debate-worthy mechanism or quality claim, not just a restatement of the analysis title. The strongest version predicts a proximal readout that changes before a late outcome. For this AD master-plan preregistration, the debate should preserve the named strata and entities: GFAP, AD, tau, amyloid.
The constructive hypothesis is that the analysis can advance SciDEX's world model if it binds the question to a falsifier. The priority test is resolve GFAP-positive astrocyte subtypes by spatial transcriptomics and perturb metabolic support pathways in neuron-astrocyte systems. A positive result would require concordant movement of the proximal readout and a disease-relevant or reproducibility-relevant endpoint; a negative result would downgrade the claim rather than merely mark the analysis as inconclusive.
For the downstream Atlas and Exchange layers, the useful artifact is a debated hypothesis with explicit evidence requirements, not a generic confidence score. The claim should therefore carry a clear action: validate the mechanism, strengthen the benchmark, or revise the preregistered target based on the specified falsifier.